Drug intelligence / Profile preview

APG-115 + toripalimab

Development stage: Unknown
Lead developer: Ascentage Pharma
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous

Overview

**APG-115 + toripalimab** is a combination therapy under clinical investigation for advanced solid tumors, primarily advanced liposarcoma, malignant peripheral nerve sheath tumor, biliary-tract cancer, and adenoid cystic carcinoma. APG-115 (alrizomadlin) is a selective, orally administered small-molecule inhibitor of MDM2, designed to block the MDM2-p53 interaction and thereby activate the tumor-suppressor activity of p53. Toripalimab (JS001) is a humanized monoclonal antibody that inhibits the programmed cell death-1 (PD-1) receptor, promoting T-cell anti-tumor activity. The combination is intended to synergistically enhance anti-tumor immune responses and has shown promising safety and early efficacy signals in phase Ib/II trials[1][4][3].

Other names: APG-115 + toripalimabalrizomadlin + toripalimab

Targets

PDCD1 (Programmed cell death protein 1 receptor)MDM2 (Mouse double minute 2 homolog)

Beyond the preview

Go deeper on APG-115 + toripalimab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APG-115 + toripalimab.

Explore the full profile